Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 408

Related Citations for PubMed (Select 19355843)

1.

Cholinesterase inhibitors and beyond.

Pepeu G, Giovannini MG.

Curr Alzheimer Res. 2009 Apr;6(2):86-96. Review.

PMID:
19355843
2.

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.

Drugs Aging. 2004;21(7):453-78. Review.

PMID:
15132713
3.

Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.

Haywood WM, Mukaetova-Ladinska EB.

Am J Geriatr Pharmacother. 2006 Sep;4(3):273-86. Review.

PMID:
17062329
4.

The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

Inglis F.

Int J Clin Pract Suppl. 2002 Jun;(127):45-63. Review.

PMID:
12139367
5.

Cholinesterase inhibitors and memory.

Pepeu G, Giovannini MG.

Chem Biol Interact. 2010 Sep 6;187(1-3):403-8. doi: 10.1016/j.cbi.2009.11.018. Epub 2009 Nov 24. Review.

PMID:
19941841
6.

Cholinesterase inhibitors for Alzheimer's disease.

Grutzendler J, Morris JC.

Drugs. 2001;61(1):41-52. Review.

PMID:
11217870
7.

Pharmacology and clinical efficacy of cholinesterase inhibitors.

Jann MW.

Am J Health Syst Pharm. 1998 Nov 1;55 Suppl 2:S22-5. Review.

PMID:
9809108
8.

Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.

Greig NH, Lahiri DK, Sambamurti K.

Int Psychogeriatr. 2002;14 Suppl 1:77-91. Review.

PMID:
12636181
9.

Switching cholinesterase inhibitors in patients with Alzheimer's disease.

Emre M.

Int J Clin Pract Suppl. 2002 Jun;(127):64-72. Review.

PMID:
12139369
10.

Treatment of Alzheimer's disease in the long-term-care setting.

Smith DA.

Am J Health Syst Pharm. 2009 May 15;66(10):899-907. doi: 10.2146/ajhp070622. Review.

PMID:
19420308
11.
12.

Targeting acetylcholinesterase and butyrylcholinesterase in dementia.

Lane RM, Potkin SG, Enz A.

Int J Neuropsychopharmacol. 2006 Feb;9(1):101-24. Epub 2005 Aug 5. Review.

PMID:
16083515
13.

To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease.

Diniz BS, Pinto JA Jr, Gonzaga ML, Guimarães FM, Gattaz WF, Forlenza OV.

Eur Arch Psychiatry Clin Neurosci. 2009 Jun;259(4):248-56. doi: 10.1007/s00406-008-0864-1. Epub 2009 Feb 17.

PMID:
19224111
15.

[Rivastigmine: a review of its clinical effectiveness].

Spiegel R.

Rev Neurol. 2002 Nov 1-15;35(9):859-69. Review. Spanish.

16.

Have cholinergic therapies reached their clinical boundary in Alzheimer's disease?

Jones RW.

Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S7-S13. Review.

PMID:
12973745
17.

A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.

Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, Lee B, Ingram DK, Lahiri DK.

Curr Med Res Opin. 2001;17(3):159-65. Review.

PMID:
11900310
18.

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease.

Krall WJ, Sramek JJ, Cutler NR.

Ann Pharmacother. 1999 Apr;33(4):441-50. Review.

PMID:
10332536
19.

An update on the pharmacology of galantamine.

Villarroya M, García AG, Marco-Contelles J, López MG.

Expert Opin Investig Drugs. 2007 Dec;16(12):1987-98. Review.

PMID:
18042006
20.

Cholinesterase inhibitors: new roles and therapeutic alternatives.

Giacobini E.

Pharmacol Res. 2004 Oct;50(4):433-40. Review.

PMID:
15304240
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk